Merck counts 50,000 Vioxx registrants

The deadline bell has rung. At final count, more than 50,000 Vioxx plaintiffs have registered for the $4.85 billion settlement.

By registering, they're not committing to take the deal, only to submit their info so that Merck lawyers can verify the various claims. Only cases involving patients who had a heart attack or stroke, or who died, are eligible. And only after eligibility is verified will we know whether the deal might go through. Eight-five percent of the plaintiffs have to accept their share of the money pool for Merck to finance the settlement.

- read the update from CNN Money

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.